GlassScriptPhysician profile
James R Hart
NPI 1215915871
$53,092.52
in general payments reported to CMS, 2019-2025
28 companies · $10K in 2025
The $10K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,398 · 2020: $1,205 · 2021: $1,303 · 2022: $1,206 · 2023: $18K · 2024: $14K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Food and Beverage: $3,684 · Travel and Lodging: $417 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,751.00 |
| Food and Beverage | $3,683.83 |
| Travel and Lodging | $416.79 |
| Education | $129.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $45,258.45 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $1,195.13 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $976.04 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $973.82 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $967.66 | 2019-2025 | Invega Sustenna, Spravato |
| Neurocrine Biosciences, INC. | $750.99 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $484.06 | 2019-2025 | Abilify Maintena, Rexulti, Nuedexta |
| Sunovion Pharmaceuticals INC. | $464.71 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $353.39 | 2019-2025 | Trintellix |
| Lundbeck LLC | $341.97 | 2019-2025 | Rexulti, Brintellix |
| Avanir Pharmaceuticals, INC. | $283.14 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $269.55 | 2024-2025 | Cobenfy |
| Abbvie INC. | $156.39 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $151.67 | 2020-2023 | Belsomra |
| Axsome Therapeutics, INC. | $108.57 | 2022-2025 | Auvelity |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $79.31 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $53.47 | 2021 | |
| Noven Therapeutics, LLC | $52.47 | 2021 | |
| Almatica Pharma LLC | $42.05 | 2021-2022 | |
| Luye Pharma (USA) LTD. | $28.08 | 2025 | Erzofri Extended-Release |
| Allergan, INC. | $25.65 | 2019 | |
| Harmony Biosciences LLC | $24.33 | 2023 | Wakix |
| Novartis Pharmaceuticals Corporation | $20.27 | 2019 | |
| Indivior INC. | $16.54 | 2021 | |
| Adlon Therapeutics L.P. | $14.81 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.